Abstract
Background: In cancers, maintenance of telomeres often occurs through activation of the catalytic subunit of telomerase, encoded by TERT. Yet, most cancers show only modest levels of TERT gene expression, even in the context of activating hotspot promoter mutations (C228T and C250T). The role of epigenetic mechanisms, including DNA methylation, in regulating TERT gene expression in cancer cells is as yet not fully understood. Methods: Here, we have carried out the most comprehensive characterization to date of TERT promoter methylation using ultra-deep bisulfite sequencing spanning the CpG island surrounding the core TERT promoter in 96 different human cell lines, including primary, immortalized and cancer cell types, as well as in control and reference samples. Results: In general, we observed that immortalized and cancer cell lines were hypermethylated in a region upstream of the recurrent C228T and C250T TERT promoter mutations, while non-malignant primary cells were comparatively hypomethylated in this region. However, at the allele-level, we generally found that hypermethylation of promoter sequences in cancer cells is associated with repressed expression, and the remaining unmethylated alleles marked with open chromatin are largely responsible for the observed TERT expression in cancer cells. Conclusions: Our findings suggest that hypermethylation of the TERT promoter alleles signals transcriptional repression of those alleles, leading to attenuation of TERT activation in cancer cells. This type of fine tuning of TERT expression may account for the modest activation of TERT expression in most cancers.
Original language | English (US) |
---|---|
Pages (from-to) | 847-861 |
Number of pages | 15 |
Journal | Cellular oncology (Dordrecht) |
Volume | 43 |
Issue number | 5 |
DOIs | |
State | Published - Oct 1 2020 |
Funding
This work was supported in part by grants from the NIH/NCI (P50CA058236, U01CA196390, R01CA183965), Commonwealth Foundation, and the Prostate Cancer Foundation, the V Foundation For Cancer Research, the Masenheimer Fund, the Irving Hansen Foundation, and the Patrick C. Walsh Award. Acknowledgements Availability of data and materials The pNL1.1 vector was a kind gift of May Guo (Promega). We thank Dr. Theodore L. DeWeese for helpful discussions. We thank the members of the SKCCC Experimental and Computational Genomics Core, supported by a Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Regional Oncology Center Grant (NIH/NCI P30CA006973). The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. The pNL1.1 vector was a kind gift of May Guo (Promega). We thank Dr. Theodore L. DeWeese for helpful discussions. We thank the members of the SKCCC Experimental and Computational Genomics Core, supported by a Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Regional Oncology Center Grant (NIH/NCI P30CA006973).
Keywords
- Cancer
- DNA methylation
- Epigenetics
- High-throughput sequencing
- TERT promoter mutation
- Telomerase regulation
- Telomeres and telomerase
ASJC Scopus subject areas
- Molecular Medicine
- Oncology
- Cancer Research